Paris (France), Cambridge (Massachusetts, US), Monday October 31, 2022, 11:00 p.m. CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a biotechnology company clinic specializing in the development of treatments aimed at slowing the degenerative processes associated with aging and improving the functional results of patients suffering from age-related diseases, including respiratory failure in patients suffering from COVID-19, publishes its main financial aggregates as of June 30, 2022 and announces that the audited consolidated financial statements previously published by the Company for the financial year ended December 31, 2021 are being restated to correct the accounting treatment of the Kréos financing contract signed in November 2021.
Financial items (unaudited)
• Cash position of €19.7 million as of June 30, 2022 versus
€23.9 million as of December 31, 2021
• Operating loss of €11.9 million in the 1st half of 2022 compared to €10.5 million in the 1st half of 2021, resulting from an increase in the cost of share-based payments due to their accounting treatment under IFRS2, in part offset by lower clinical trial costs